Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute-Reference-Cited by-同舟云学术

Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute

Published:2021 Issue:1 Volume:35 Page:373-384
ISSN:0258-851X
Container-title:In Vivo
language:en
Short-container-title:In Vivo

Author:

MIYAZAWA YOSHIYUKI,SEKINE YOSHITAKA,ARAI SEIJI,OKA DAISUKE,NAKAYAMA HIROSHI,SYUTO TAKAHIRO,NOMURA MASASHI,KOIKE HIDEKAZU,MATSUI HIROSHI,SHIBATA YASUHIRO,SUZUKI KAZUHIRO

Publisher

Anticancer Research USA Inc.

Subject

Pharmacology,General Biochemistry, Genetics and Molecular Biology,Cancer Research

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide;International Journal of Clinical Oncology;2024-08-17

2. Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer;International Journal of Clinical Oncology;2024-04-08

3. Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer;The World Journal of Men's Health;2024

4. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

5. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer;Drug Resistance Updates;2022-09